|Videos|July 18, 2014
Optimizing Checkpoint Inhibition in NSCLC
Advertisement
Episodes in this series
For High-Definition, Click
The response rate with PD-1 inhibition in non-small cell lung cancer (NSCLC) is approximately 20% to 40%, depending on PD-L1 status. For patients who do not respond to single-agent PD-1 inhibition, combination strategies could be utilized to further improve outcomes.
The Lung-MAP study is currently assessing various treatment options based on molecular characteristics. In addition to immunotherapy, this study will also assess platinum-based chemotherapy.
View the video, to hear the discussion.
Advertisement
Related to this article
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5